{"id":556,"date":"2015-05-04T15:22:56","date_gmt":"2015-05-04T09:52:56","guid":{"rendered":"https:\/\/delveinsightblog.wordpress.com\/?p=556"},"modified":"2025-05-05T17:37:46","modified_gmt":"2025-05-05T12:07:46","slug":"telomerase-inhibitors-an-anti-cancer-approach","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/telomerase-inhibitors-an-anti-cancer-approach","title":{"rendered":"Telomerase Inhibitors \u2013 An Anti Cancer Approach"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69fd06158e602\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69fd06158e602\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><ul class='ez-toc-list-level-6' ><li class='ez-toc-heading-level-6'><ul class='ez-toc-list-level-6' ><li class='ez-toc-heading-level-6'><ul class='ez-toc-list-level-6' ><li class='ez-toc-heading-level-6'><ul class='ez-toc-list-level-6' ><li class='ez-toc-heading-level-6'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/telomerase-inhibitors-an-anti-cancer-approach\/#The_current_cancer_therapies_and_drug_design_strategies_developed_are_more_precisely_aimed_at_targeting_the_cancer_cells_Primary_challenge_in_selectively_targeting_cancer_cells_is_to_differentiate_between_the_cancer_cells_and_the_normal_cells_One_such_difference_is_enzyme_telomerase_activity_which_has_been_an_exciting_drug_target_as_it_is_active_in_almost_85%E2%80%9490_of_all_human_cancers_but_is_inactive_in_normal_human_cells_Telomerase_is_a_ribonucleoprotein_that_synthesizes_telomeres_The_increase_in_the_activity_of_telomerase_is_seen_very_early_during_tumorigenesis_and_techniques_such_as_the_telomeric_repeat_amplification_protocol_TRAP_assay_have_been_useful_in_measurements_of_telomerase_activity\" >The current cancer therapies and drug design strategies developed are more precisely aimed at targeting the cancer cells. Primary challenge in selectively targeting cancer cells is to differentiate between the cancer cells and the normal cells. One such difference is enzyme telomerase activity which has been an exciting drug target as it is active in almost 85\u201490% of all human cancers but is inactive in normal human cells. Telomerase is a ribonucleoprotein that synthesizes telomeres. The increase in the activity of telomerase is seen very early during tumorigenesis and techniques such as the telomeric repeat amplification protocol (TRAP) assay have been useful in measurements of telomerase activity.<\/a><\/li><\/ul><\/li><\/ul><\/li><\/ul><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/telomerase-inhibitors-an-anti-cancer-approach\/#Molecular_targets_for_Telomerase_Inhibition\" >Molecular targets for Telomerase Inhibition<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/telomerase-inhibitors-an-anti-cancer-approach\/#Current_Pipeline_Scenario-_A_Graph_Representation\" >Current Pipeline Scenario- A Graph Representation<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/telomerase-inhibitors-an-anti-cancer-approach\/#Telomerase_Inhibitors_in_Pipeline_and_Major_Players\" >Telomerase Inhibitors in Pipeline and Major Players<\/a><ul class='ez-toc-list-level-4' ><li class='ez-toc-heading-level-4'><ul class='ez-toc-list-level-4' ><li class='ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/telomerase-inhibitors-an-anti-cancer-approach\/#Report_Telomerase_Inhibitors-Pipeline_Insights_2015\" >Report: Telomerase Inhibitors-Pipeline Insights, 2015<\/a><\/li><\/ul><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<p><img decoding=\"async\" class=\"  wp-image-558 alignright\" src=\"https:\/\/delveinsightblog.files.wordpress.com\/2015\/04\/delveinsight_telomerase.jpg?w=300\" alt=\"DelveInsight_Telomerase\" width=\"532\" height=\"187\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2015\/05\/09053724\/delveinsight_telomerase-630x222.jpg 630w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2015\/05\/09053724\/delveinsight_telomerase-20x7.jpg 20w\" sizes=\"(max-width: 532px) 100vw, 532px\" \/><\/p>\n<h6 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"The_current_cancer_therapies_and_drug_design_strategies_developed_are_more_precisely_aimed_at_targeting_the_cancer_cells_Primary_challenge_in_selectively_targeting_cancer_cells_is_to_differentiate_between_the_cancer_cells_and_the_normal_cells_One_such_difference_is_enzyme_telomerase_activity_which_has_been_an_exciting_drug_target_as_it_is_active_in_almost_85%E2%80%9490_of_all_human_cancers_but_is_inactive_in_normal_human_cells_Telomerase_is_a_ribonucleoprotein_that_synthesizes_telomeres_The_increase_in_the_activity_of_telomerase_is_seen_very_early_during_tumorigenesis_and_techniques_such_as_the_telomeric_repeat_amplification_protocol_TRAP_assay_have_been_useful_in_measurements_of_telomerase_activity\"><\/span>The current cancer therapies and drug design strategies developed are more precisely aimed at targeting the cancer cells. Primary challenge in selectively targeting cancer cells is to differentiate between the cancer cells and the normal cells. One such difference is enzyme telomerase activity which has been an exciting drug target as it is active in almost 85\u201490% of all human cancers but is inactive in normal human cells. Telomerase is a ribonucleoprotein that synthesizes telomeres. The increase in the activity of telomerase is seen very early during tumorigenesis and techniques such as the telomeric repeat amplification protocol (TRAP) assay have been useful in measurements of telomerase activity.<span class=\"ez-toc-section-end\"><\/span><\/h6>\n<h2 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Molecular_targets_for_Telomerase_Inhibition\"><\/span>Molecular targets for Telomerase Inhibition<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p style=\"text-align: justify;\">There are multiple molecular targets discovered in past towards telomerase based anticancer approach. The approaches have been directed at inhibiting all aspects of telomeres or telomerase biology through <strong><span style=\"color: #ff6600;\">immunotherapy vaccines<\/span><\/strong> targeting telomerase, human hTERT-specific epitopes. It inhibits the transcriptional and translational activation of hTERT. <strong><span style=\"color: #ff6600;\">Oligonucleotide<\/span><\/strong> and <strong><span style=\"color: #ff6600;\">small molecule<\/span><\/strong> is regarded as one of the standard pharmacological approach where oligodeoxynucleotides are developed complementary to the hTERT mRNA leading to rapid cancer cells death by obstructing the telomeres structure. Suicide gene therapy is an extremely effective advancement where hTERT promoter-driven expression of a toxic gene restricts the expression of the tumors. Other approaches include telomerase disrupting agents such as G-quadraplex stabilizing molecules and antisense ribozyme or small interfering RNA agents targeting TERT mRNA or hTR.<\/p>\n<h2 style=\"text-align: left;\"><span class=\"ez-toc-section\" id=\"Current_Pipeline_Scenario-_A_Graph_Representation\"><\/span>Current Pipeline Scenario- A Graph Representation<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<blockquote><p><img decoding=\"async\" class=\"  wp-image-561 aligncenter\" src=\"https:\/\/delveinsightblog.files.wordpress.com\/2015\/05\/ti.jpg?w=300\" alt=\"TI\" width=\"340\" height=\"205\" \/><\/p><\/blockquote>\n<h2 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Telomerase_Inhibitors_in_Pipeline_and_Major_Players\"><\/span>Telomerase Inhibitors in Pipeline and Major Players<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>In recent years, two major biopharmaceutical companies <strong>Geron and KAEL-Gemvax<\/strong> (South Korean company) have established themselves as pioneers in telomerase inhibition approach. Since there are no telomerase inhibitors have been approved, these two companies may lead in providing the breakthrough. KAEL- Gemvax\u2019s vaccine<span style=\"color: #800080;\"><strong> GV1001 has approached NDA after successful phase III study for pancreatic cancer. <\/strong><\/span>The company strongly believes in their lead drug candidate GV1001 as blockbuster potential and currently the most advanced therapeutic cancer vaccine in development targeting telomerase inhibition.<\/p>\n<p>Geron Corporation relies heavily on their lead drug candidate molecule <strong><span style=\"color: #003366;\">Imetelstat<\/span><\/strong> as telomerase inhibitor. In past Geron has witnessed several failures with stem cells therapies and cancer treatments thereby discontinued its all stem cell operations in 2011 and sold it to BioTime\u2019s subsidiary Asterias Biotherapeutics. <strong><span style=\"color: #ff0000;\">Geron is currently targeting the market of myelofibrosis which is dominated by Celgene, Novartis, and Incyte, although they don\u2019t have dedicated treatments. So, this represents a major opportunity for imetelstat. <\/span><\/strong>Several types of cancers are being targeted using telomerase inhibitor which represents a major inclination and interests of these firms to establish in market.<\/p>\n<p>Other companies coming up in the market with telomerase inhibiting drug candidates include Adamis pharmaceutical corporation and Oncolys Biopharma which are currently testing their drugs in clinical trials stage. With few companies reaching the clinical trial development stage and multiple cancers under investigation, telomerase inhibition remains a striking and useful target in future for biotech and pharmaceutical companies with multiple opportunities of escalation.<\/p>\n<p style=\"text-align: justify;\"><em>Written by Tarun Jain, Associate Analyst at DelveInsight<\/em><\/p>\n<h4 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Report_Telomerase_Inhibitors-Pipeline_Insights_2015\"><\/span>Report: Telomerase Inhibitors-Pipeline Insights, 2015<span class=\"ez-toc-section-end\"><\/span><\/h4>\n<p style=\"text-align: justify;\">For more information on this Report, mail us at info@delveinsight.com<\/p>\n<p style=\"text-align: justify;\"><strong><em>Lets share our knowledge, provide your comments in the\u00a0comment section<\/em><\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The current cancer therapies and drug design strategies developed are more precisely aimed at targeting the cancer cells. Primary challenge in selectively targeting cancer cells is to differentiate between the cancer cells and the normal cells. One such difference is enzyme telomerase activity which has been an exciting drug target as it is active in [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[17251,17253,137,17249,17254,17250,17252,17248],"industry":[17225],"therapeutic_areas":[17228],"class_list":["post-556","post","type-post","status-publish","format-standard","hentry","category-articles","tag-adamis-pharmaceutical","tag-asterias-biotherapeutics","tag-cancer","tag-geron","tag-imetelstat","tag-kael-gemvax","tag-oncolys-biopharma","tag-telomerase-inhibitors","industry-pharmaceutical","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Telomerase Inhibitors \u2013 An Anti Cancer Approach | DelveInsight<\/title>\n<meta name=\"description\" content=\"The current cancer therapies and drug design strategies developed are more precisely aimed at targeting the cancer cells...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/telomerase-inhibitors-an-anti-cancer-approach\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Telomerase Inhibitors \u2013 An Anti Cancer Approach | DelveInsight\" \/>\n<meta property=\"og:description\" content=\"The current cancer therapies and drug design strategies developed are more precisely aimed at targeting the cancer cells...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/telomerase-inhibitors-an-anti-cancer-approach\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2015-05-04T09:52:56+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-05T12:07:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/delveinsightblog.files.wordpress.com\/2015\/04\/delveinsight_telomerase.jpg?w=300\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Telomerase Inhibitors \u2013 An Anti Cancer Approach | DelveInsight","description":"The current cancer therapies and drug design strategies developed are more precisely aimed at targeting the cancer cells...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/telomerase-inhibitors-an-anti-cancer-approach","og_locale":"en_US","og_type":"article","og_title":"Telomerase Inhibitors \u2013 An Anti Cancer Approach | DelveInsight","og_description":"The current cancer therapies and drug design strategies developed are more precisely aimed at targeting the cancer cells...","og_url":"https:\/\/www.delveinsight.com\/blog\/telomerase-inhibitors-an-anti-cancer-approach","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2015-05-04T09:52:56+00:00","article_modified_time":"2025-05-05T12:07:46+00:00","og_image":[{"url":"https:\/\/delveinsightblog.files.wordpress.com\/2015\/04\/delveinsight_telomerase.jpg?w=300","type":"","width":"","height":""}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/telomerase-inhibitors-an-anti-cancer-approach","url":"https:\/\/www.delveinsight.com\/blog\/telomerase-inhibitors-an-anti-cancer-approach","name":"Telomerase Inhibitors \u2013 An Anti Cancer Approach | DelveInsight","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/telomerase-inhibitors-an-anti-cancer-approach#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/telomerase-inhibitors-an-anti-cancer-approach#primaryimage"},"thumbnailUrl":"https:\/\/delveinsightblog.files.wordpress.com\/2015\/04\/delveinsight_telomerase.jpg?w=300","datePublished":"2015-05-04T09:52:56+00:00","dateModified":"2025-05-05T12:07:46+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"The current cancer therapies and drug design strategies developed are more precisely aimed at targeting the cancer cells...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/telomerase-inhibitors-an-anti-cancer-approach"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/telomerase-inhibitors-an-anti-cancer-approach#primaryimage","url":"https:\/\/delveinsightblog.files.wordpress.com\/2015\/04\/delveinsight_telomerase.jpg?w=300","contentUrl":"https:\/\/delveinsightblog.files.wordpress.com\/2015\/04\/delveinsight_telomerase.jpg?w=300"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":null,"coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Adamis pharmaceutical<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Asterias Biotherapeutics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Geron<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Imetelstat<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">KAEL Gemvax<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Oncolys Biopharma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Telomerase Inhibitors<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Adamis pharmaceutical<\/span>","<span class=\"advgb-post-tax-term\">Asterias Biotherapeutics<\/span>","<span class=\"advgb-post-tax-term\">Cancer<\/span>","<span class=\"advgb-post-tax-term\">Geron<\/span>","<span class=\"advgb-post-tax-term\">Imetelstat<\/span>","<span class=\"advgb-post-tax-term\">KAEL Gemvax<\/span>","<span class=\"advgb-post-tax-term\">Oncolys Biopharma<\/span>","<span class=\"advgb-post-tax-term\">Telomerase Inhibitors<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 11 years ago","modified":"Updated 1 year ago"},"absolute_dates":{"created":"Posted on May 4, 2015","modified":"Updated on May 5, 2025"},"absolute_dates_time":{"created":"Posted on May 4, 2015 3:22 pm","modified":"Updated on May 5, 2025 5:37 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/556","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=556"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/556\/revisions"}],"predecessor-version":[{"id":31674,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/556\/revisions\/31674"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=556"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=556"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=556"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=556"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=556"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}